Research programme: atherosclerosis therapy - Immusoft

Drug Profile

Research programme: atherosclerosis therapy - Immusoft

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Immusoft
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atherosclerosis

Most Recent Events

  • 07 Jul 2016 Preclinical trials in Atherosclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top